NDAINTRAVENOUSPOWDERPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERBAXA is a fixed-dose combination intravenous antibiotic containing ceftolozane (a fifth-generation cephalosporin) and tazobactam (a beta-lactamase inhibitor) developed by Merck & Co. The product was approved by the FDA on December 19, 2014, as a powder formulation for intravenous administration. ZERBAXA is indicated for treating complicated intra-abdominal infections and complicated urinary tract infections caused by susceptible gram-negative bacteria, including multidrug-resistant organisms. The combination addresses an important treatment gap by providing enhanced activity against Pseudomonas aeruginosa and other resistant pathogens.
$0.0BPart D
9.3 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZERBAXA creates career opportunities for hospital-based brand managers, medical science liaisons focused on infectious disease specialists and hospital pharmacy directors, and hospital field teams. Professionals working on this product require expertise in hospital formulary management, infection control protocols, antibiotic stewardship programs, and gram-negative resistance patterns. Currently, zero open positions are linked to this product in available data.
Company
Worked on ZERBAXA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.